(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 11.91% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Cytosorbents's revenue in 2026 is $37,216,000.On average, 4 Wall Street analysts forecast CTSO's revenue for 2026 to be $124,595,158, with the lowest CTSO revenue forecast at $117,475,076, and the highest CTSO revenue forecast at $130,650,056. On average, 4 Wall Street analysts forecast CTSO's revenue for 2027 to be $141,502,998, with the lowest CTSO revenue forecast at $126,873,208, and the highest CTSO revenue forecast at $155,394,385.
In 2028, CTSO is forecast to generate $165,361,244 in revenue, with the lowest revenue forecast at $158,875,873 and the highest revenue forecast at $170,225,272.